ArticleBiosensors2025
Stamp-Imprinted Polymer EIS Biosensor for Amyloid-Beta Detection: A Novel Approach Towards Alzheimer's Screening.
Article in Biosensors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Overview in Electrochemical and Electrical Biosensors for Determining Blood Protein Biomarkers of Alzheimer's Disease.Biosensors · 2026Review
- Recent advances in microfluidic technologies for the detection of Alzheimer's disease biomarkers: toward point-of-care neurodiagnostic.Mikrochimica acta · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Surface-imprinted polymers (SIPs) represent an exciting and cost-effective alternative to antibodies for electrochemical impedance spectroscopy (EIS)-based biosensing. They can be produced using simple printing techniques and have shown high efficacy in detecting large biomolecules and microorganisms. Stamp imprinting, a novel SIP method, creates the target analyte's imprint using a soft lithography mask of the analyte matrix, thereby reducing material complexities and eliminating the need for cross-linking, which makes the process more scalable than the conventional SIPs. In this work, we demonstrate a stamp-imprinted EIS biosensor using a biocompatible polymer, polycaprolactone (PCL), for quantifying amyloid beta-42 (Aβ-42), a small peptide involved in the pathophysiology of Alzheimer's disease. The evaluated SIP-EIS biosensors showed a detection limit close to 10 fg/mL, and a detection range covering the physiologically relevant concentration range of the analyte in blood serum (from 10 fg/mL to 10 μg/mL). The device sensitivity, which is found to be comparable to antibody-based EIS devices, demonstrates the potential of SIP-EIS biosensors as an exciting alternative to conventional antibody-based diagnostic approaches. We also evaluate the viability of analyzing these proteins in complex media, notably in the presence of serum albumin proteins, which cause biofouling and non-specific interactions. The combination of high sensitivity, selectivity, and ease of fabrication makes SIP-EIS biosensors particularly suited for portable and point-of-care applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.